CD80 expression is upregulated by TP53 activation in human cancer epithelial cells

References

• Brown CJ, Lain S, Verma CS, Fersht AR, Lane DP. Awakening guardian angels: drugging the p53 pathway. Nat Rev Cancer. 2009;9(12):862–6. doi:10.1038/nrc2763.
   PubMed Web of Science ®Google Scholar
• Braun MW, Iwakuma T. Regulation of cytotoxic T-cell responses by p53 in cancer. Transl Cancer Res. 2016;5(6):692–697. doi:10.21037/tcr.2016.11.76.
   PubMed Web of Science ®Google Scholar
• Blagih J, Buck MD, Vousden KH. p53, cancer and the immune response. J Cell Sci. 2020;133(5):jcs237453. doi:10.1242/jcs.237453.
   PubMed Web of Science ®Google Scholar
• Levine AJ. P53 and The Immune Response: 40 Years of Exploration—A Plan for the Future. Int J Mol Sci. 2020;21(2):541. doi:10.3390/ijms21020541.
   PubMed Web of Science ®Google Scholar
• Driessens G, Kline J, Gajewski TF. Costimulatory and coinhibitory receptors in anti-tumor immunity. Immunol Rev. 2009;229(1):126–144. doi:10.1111/j.1600-065X.2009.00771.x.
   PubMed Web of Science ®Google Scholar
• Chen R, Ganesan A, Okoye I, Arutyunova E, Elahi S, Lemieux MJ, Barakat K. Targeting B7-1 in immunotherapy. Med Res Rev. 2020;40(2):654–682. doi:10.1002/med.21632.
   PubMed Web of Science ®Google Scholar
• Marchiori C, Scarpa M, Kotsafti A, Morgan S, Fassan M, Guzzardo V, Porzionato A, Angriman I, Ruffolo C, Sut S, et al. Epithelial CD80 promotes immune surveillance of colonic preneoplastic lesions and its expression is increased by oxidative stress through STAT3 in colon cancer cells. Journal of Experimental & Clinical Cancer Research. 2019;38(1):190. doi:10.1186/s13046-019-1205-0.
   PubMed Web of Science ®Google Scholar
• Scarpa M, Fassan M, Kotsafti A, Realdon S, Dall’Olmo L, Morbin T, Cavallin F, Saadeh L, Cagol M, Alfieri R, et al. CD80 expression promotes immune surveillance in Barrett’s metaplasia. OncoImmunology. 2019;8(10):e1636618. doi:10.1080/2162402X.2019.1636618.
   PubMed Web of Science ®Google Scholar
• Scarpa M, Brun P, Scarpa M, Morgan S, Porzionato A, Kotsafti A, Bortolami M, Buda A, D’Incà R, Macchi V, et al. CD80-CD28 signaling controls the progression of inflammatory colorectal carcinogenesis. Oncotarget. 2015;6(24):20058–20069. doi:10.18632/oncotarget.2780.
   PubMedGoogle Scholar
• Tirapu I, Huarte E, Guiducci C, Arina A, Zaratiegui M, Murillo O, Gonzalez A, Berasain C, Berraondo P, Fortes P, et al. Low Surface Expression of B7-1 (CD80) Is an Immunoescape Mechanism of Colon Carcinoma. Cancer Res. 2006;66(4):2442–2450. doi:10.1158/0008-5472.CAN-05-1681.
   PubMed Web of Science ®Google Scholar
• Scarpa M, Ruffolo C, Canal F, Scarpa M, Basato S, Erroi F, Fiorot A, Dall’Agnese L, Pozza A, Porzionato A, et al. Mismatch repair gene defects in sporadic colorectal cancer enhance immune surveillance. Oncotarget. 2015;6(41):43472–43482. doi:10.18632/oncotarget.6179.
   PubMedGoogle Scholar
• Hu J, Batth IS, Xia X, Li S. Regulation of NKG2D+CD8+ T-cell-mediated antitumor immune surveillance: identification of a novel CD28 activation-mediated, STAT3 phosphorylation-dependent mechanism. OncoImmunology. 2016;5(12):e1252012. doi:10.1080/2162402X.2016.1252012.
   PubMed Web of Science ®Google Scholar
• Haile ST, Bosch JJ, Agu NI, Zeender AM, Somasundaram P, Srivastava MK, Britting S, Wolf JB, Ksander BR, Tumor Cell O-RS. Programmed Death Ligand 1-Mediated T Cell Suppression Is Overcome by Coexpression of CD80. J Immunol. 2011;186(12):6822–6829. doi:10.4049/jimmunol.1003682.
   PubMed Web of Science ®Google Scholar
• Luque I, Reyburn H, Strominger JL. Expression of the CD80 and CD86 molecules enhances cytotoxicity by human natural killer cells. Hum Immunol. 2000;61(8):721–728. doi:10.1016/S0198-8859(00)00136-1.
   PubMed Web of Science ®Google Scholar
• Canel M, Taggart D, Sims AH, Lonergan DW, Waizenegger IC, Serrels A. T-cell co-stimulation in combination with targeting FAK drives enhanced anti-tumor immunity . eLife. 2020;9:e48092. Kawakami Y, Settleman J, editors. doi:10.7554/eLife.48092.
   PubMed Web of Science ®Google Scholar
• Moore EC, Sun L, Clavijo PE, Friedman J, Harford JB, Saleh AD, Van Waes C, Chang EH, Allen CT. Nanocomplex-based TP53 gene therapy promotes anti-tumor immunity through TP53-and STING-dependent mechanisms. Oncoimmunology. 2018;7(7). doi:10.1080/2162402X.2017.1404216
   Google Scholar
• CD80 as a Biomarker of p53 Activity and Target for Cancer Therapy | MIT Technology Licensing Office. [accessed February 17, 2021. http://tlo.mit.edu/technologies/cd80-biomarker-p53-activity-and-target-cancer-therapy.
   Google Scholar
• Fischer M. Conservation and divergence of the p53 gene regulatory network between mice and humans. Oncogene. 2019;38(21):4095–4109. doi:10.1038/s41388-019-0706-9.
   PubMed Web of Science ®Google Scholar
• Liu J, Lichtenberg T, Hoadley KA, Poisson LM, Lazar AJ, Cherniack AD, Kovatich AJ, Benz CC, Levine DA, Lee AV, et al. An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics. Cell. 2018;173(2):400–416.e11. doi:10.1016/j.cell.2018.02.052.
   PubMed Web of Science ®Google Scholar
• Cerami E, Gao J, Dogrusoz U, Be G, So S, Ba A, Jacobsen A, Cj B, Ml H, Larsson E, et al. The cBio Cancer Genomics Portal: an Open Platform for Exploring Multidimensional Cancer Genomics Data. Cancer Discov. 2012;2(5):401–404. doi:10.1158/2159-8290.CD-12-0095.
   PubMed Web of Science ®Google Scholar
• Donehower LA, Soussi T, Korkut A, Liu Y, Schultz A, Cardenas M, Li X, Babur O, Hsu T-K, Lichtarge O, et al. Integrated Analysis of TP53 Gene and Pathway Alterations in The Cancer Genome Atlas. Cell Rep. 2019;28(5):1370–1384.e5. doi:10.1016/j.celrep.2019.07.001.
   PubMed Web of Science ®Google Scholar
• Quigley D, Silwal-Pandit L, Dannenfelser R, Langerød A, Vollan HKM, Vaske C, Siegel JU, Troyanskaya O, Chin S-F, Caldas C, et al. Lymphocyte Invasion in IC10/Basal-Like Breast Tumors Is Associated with Wild-Type TP53. Mol Cancer Res. 2015;13(3):493–501. doi:10.1158/1541-7786.MCR-14-0387.
   PubMed Web of Science ®Google Scholar
• Jiang Z, Liu Z, Li M, Chen C, Wang X. Immunogenomics Analysis Reveals that TP53 Mutations Inhibit Tumor Immunity in Gastric Cancer. Transl Oncol. 2018;11(5):1171–1187. doi:10.1016/j.tranon.2018.07.012.
   PubMed Web of Science ®Google Scholar
• Blagih J, Zani F, Chakravarty P, Hennequart M, Pilley S, Hobor S, Hock AK, Walton JB, Morton JP, Gronroos E, et al. Cancer-Specific Loss of p53 Leads to a Modulation of Myeloid and T Cell Responses. Cell Rep. 2020;30(2):481–496.e6. doi:10.1016/j.celrep.2019.12.028.
   PubMed Web of Science ®Google Scholar
• Guo G, Yu M, Xiao W, Celis E, Cui Y. Local activation of p53 in the tumor microenvironment overcomes immune suppression and enhances antitumor immunity. Cancer Res. 2017;77(9):2292–2305. doi:10.1158/0008-5472.CAN-16-2832.
   PubMed Web of Science ®Google Scholar
• DeLeo AB, Appella E. The p53 Saga: early Steps in the Development of Tumor Immunotherapy. The Journal of Immunology. 2020;204(9):2321–2328. doi:10.4049/jimmunol.1901343.
   PubMed Web of Science ®Google Scholar
• Sanz G, Singh M, Peuget S, Selivanova G. Inhibition of p53 inhibitors: progress, challenges and perspectives. J Mol Cell Biol. 2019;11(7):586–599. doi:10.1093/jmcb/mjz075.
   PubMed Web of Science ®Google Scholar
• Robles AI, Jen J, Harris CC. Clinical Outcomes of TP53 Mutations in Cancers. Cold Spring Harb Perspect Med. 2016;6(9):a026294. doi:10.1101/cshperspect.a026294.
   PubMed Web of Science ®Google Scholar